Company / Cost of Revenue
Merck & Co. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$16.4B
FY2025
5-year range
$13.6B / $17.4B
FY2021-FY2025
Trend
+7.8%
vs FY2024
Sector context
#3 of 85
Health Care
What the data says
Among 85 Health Care companies, Merck & Co. is in the bottom 4% for cost of revenue. Cost of Revenue returned to growth in FY2025 after 2 years of decline, reaching $16.4B.
Based on SEC 10-K filings.
$16.4B in FY2025 with a 5-year CAGR of +3.8%. Ranks 3rd among 85 companies in Health Care.
Remained stable around $16.4B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- +3.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 85This company $16.4B Sector average $2.0B
▼
+726.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 7.8% year-over-year.
- Ranks #3 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.4B | +7.8% |
| FY2024 | $15.2B | -5.8% |
| FY2023 | $16.1B | -7.4% |
| FY2022 | $17.4B | +27.8% |
| FY2021 | $13.6B | +0.1% |
| FY2020 | $13.6B | +13.3% |
| FY2019 | $12.0B | -11.1% |
| FY2018 | $13.5B | +4.6% |
| FY2017 | $12.9B | -8.0% |
| FY2016 | $14.0B | -6.1% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026